DR info

Clinical trials : 38 / Drugs : 38 - (DrugBank : 15) / Drug target genes : 18 - Drug target pathways : 118

Lymphangioleiomyomatosis and other diseases between which drug repositioning (DR) might occur (Sakate and Kimura 2021) . Circle size: Number of drugs, Line breadth: Score (Drug repositionability)

ID	Diseases (Sorted by score)	Score
89	Lymphangioleiomyomatosis	-
85	Idiopathic interstitial pneumonia	18.831
34	Neurofibromatosis	14.600
86	Pulmonary arterial hypertension	11.774
6	Parkinson disease	11.273
13	Multiple sclerosis/Neuromyelitis optica	11.106
51	Scleroderma	10.404
2	Amyotrophic lateral sclerosis	7.808
227	Osler disease	7.599
102	Rubinstein-Taybi syndrome	7.000
256	Muscle glycogenosis	6.795
331	Idiopathic multicentric castleman disease	5.735
222	Primary nephrotic syndrome	5.657
228	Bronchiolitis obliterans	5.612
233	Wolfram syndrome	5.114
5	Progressive supranuclear palsy	4.672
65	Primary immunodeficiency	4.403
3	Spinal muscular atrophy	4.019
87	Pulmonary veno-occlusive disease	4.000
28	Systemic amyloidosis	3.818
67	Polycystic kidney disease	3.556
127	Frontotemporal lobar degeneration	3.496
90	Retinitis pigmentosa	3.289
26	HTLV-1-associated myelopathy	2.770
46	Malignant rheumatoid arthritis	2.614
35	Pemphigus	2.606
276	Achondroplasia	1.933
88	Chronic thromboembolic pulmonary hypertension	1.641
158	Tuberous sclerosis	1.508
96	Crohn disease	1.500
58	Hypertrophic cardiomyopathy	1.350
215	Tetralogy of Fallot	1.350
8	Huntington disease	1.168
49	Systemic lupus erythematosus	1.105
162	Pemphigoid	1.006
137	Focal cortical dysplasia	1.000
192	Cockayne syndrome	1.000
277	Lymphangiomatosis	1.000
281	Klippel-Trenaunay-Weber syndrome	1.000
111	Congenital myopathy	1.000